David de Graaf, Abcuro CEO (Photo: Partners Innovation Fund)
Abcuro will take an anti-KLRG1 antibody into the clinic with new funding, and has big plans for another
A little over two years after pulling in its first Series A raise, autoimmune disease and cancer player Abcuro has some more cash to play …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
